Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

No Link Found Between LCIS and Local Recurrence

February 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

BOSTON-Neither the presence nor the extent of lobular carcinoma in situ (LCIS) is related to risk of local recurrence in patients with invasive breast cancer treated with conservative surgery and radiotherapy, a retrospective study from the Joint Center for Radiation Therapy has shown.

BOSTON—Neither the presence nor the extent of lobular carcinoma insitu (LCIS) is related to risk of local recurrence in patients with invasivebreast cancer treated with conservative surgery and radiotherapy, a retrospectivestudy from the Joint Center for Radiation Therapy has shown.

"This is very different from the situation with associated DCIS,"Stuart Schnitt, MD, said at a general session. Joint Center data show thatinfiltrating ductal carcinoma with a large amount of associated DCIS hasa five-year local recurrence rate of 24% vs 6% when there is little orno DCIS.

The LCIS study included 858 patients with clinical stage I or II infiltratingductal carcinoma (782 patients), infiltrating lobular carcinoma (44 patients),or infiltrating carcinoma with mixed ductal and lobular features (32 patients),treated with conservative surgery and radiotherapy.

Overall, neither local recurrence nor the incidence of distant failurewas related to histologic type. In terms of LCIS, 4% of patients with infiltratingductal cancer had associated LCIS. Not surprisingly, the vast majority(93%) of patients with infiltrating lobular carcinoma had associated LCIS.Of the patients with mixed ductal/lobular features, 59% had associatedLCIS.

Other prognostic factors for local recurrence were equally distributedamong the three groups and among those with and without LCIS. The mostimportant prognostic factor, margin status, was unknown in most patients.

The investigators then looked at the 10-year crude rate of local recurrenceamong patients with and without LCIS. Patients with infiltrating ductalcarcinoma and no LCIS had a local recurrence rate of 14% vs 10% for thosefew patients in whom LCIS was present. Among infiltrating lobular carcinomas,there were no local recurrences in the three patients without LCIS, andfive (12%) among the patients with LCIS.

For patients with mixed features, local recurrence was 15% with no LCIS,and 16% with LCIS. None of these differences were significant. Similarly,the extent of LCIS was not associated with the risk of local recurrencein any group. Based on these results, Dr. Schnitt suggests that the presenceof associated LCIS should not influence local management of infiltratingductal, lobular, or mixed carcinoma.

Articles in this issue

NCI Launches Trial of High-Dose Chemo for Advanced Ovarian Cancer
Brachytherapy to Tumor Bed After Lumpectomy a Possible Alternative to External Beam Therapy
Breast Conservation Is Contraindicated in Less Than 25% of Early-Stage Patients
'More May Be Less' in Metastatic Cervical Cancer
At 10 Years, DCIS Patients' Risk of Breast Cancer Death Is Very Low
Tumor Cells in Marrow May Better Predict Metastases Than Axillary Node Dissection
Survey Finds 122 New Anti-HIV Medicines Currently Being Tested
Delaying Radiotherapy to Allow Adjuvant Chemotherapy Not Shown to Increase Ipsilateral Recurrence Risk
President Clinton Unveils National AIDS Policy
Mammotomy May Reduce Biopsy Sampling Errors
Ultrasound Advances May Expand Role in Treatment Planning
Bills to Regulate Managed Care Are Introduced
NIH Consensus Development Statement Sparks Rancor
Breast Cancer Patients May Overestimate the Benefits of Adjuvant Chemotherapy
Letrozole Superior to Progestin as Second-Line Postmenopausal Advanced Breast Cancer Therapy
Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer

ONCOLOGY Staff
October 31st 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Allireza Alloo, MD

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Tim Cortese
October 27th 2025
Article

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC

Kristie L. Kahl
October 23rd 2025
Article

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.


Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.

Related Content
Advertisement

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer

ONCOLOGY Staff
October 31st 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Allireza Alloo, MD

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Tim Cortese
October 27th 2025
Article

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC

Kristie L. Kahl
October 23rd 2025
Article

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.


Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.